Phase I Trial of Rosiglitazone in FSGS: I. Report of the FONT Study Group

Background and objectives: Patients with primary focal segmental glomerulosclerosis (FSGS) who are resistant to standard therapy are at high risk for progressive chronic kidney disease. Prevention of renal fibrosis represents a promising strategy to slow or halt kidney function decline. This paper p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Joy, Melanie S., Gipson, Debbie S., Dike, Mary, Powell, Leslie, Thompson, Amber, Vento, Suzanne, Eddy, Allison, Fogo, Agnes B., Kopp, Jeffrey B., Cattran, Daniel, Trachtman, Howard
Format: Artigo
Jezik:Inglês
Izdano: American Society of Nephrology 2009
Teme:
Clinical Nephrology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2615712/
https://ncbi.nlm.nih.gov/pubmed/19073787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.02310508
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items